Treatment of comorbid opiate addiction and attention-deficit hyperactivity disorder (residual type) with moclobemide: a case report.
Moclobemide is a specific and reversible monoamine oxidase-A (MAO-A) inhibitor. Studies show that it is an effective and well-tolerated treatment for attention-deficit hyperactivity disorder (ADHD). A number of reports suggest that ADHD may have a causal influence on the development of substance use disorders. The authors describe the use of moclobemide in a 27-year-old patient with comorbid opiate addiction and ADHD (residual type). The positive clinical response shown suggests that moclobemide may have a particular interest in the treatment of drug-dependent patients with current ADHD.
Vaiva
Guillaume
G
Crisis Center, School of Medicine, Lille University Hospital, France. gvaiva@chru-lille.fr
De Lenclave
Marie Bérengère De Chouly
MB
Bailly
Daniel
D
D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D017831:Diagnosis, Dual (Psychiatry) / Q000523:psychology; D006801:Humans; D008297:Male; D020912:Moclobemide / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000523:psychology
D020912:Moclobemide